State of New Jersey Common Pension Fund D Buys 800 Shares of Glaukos Corporation $GKOS

State of New Jersey Common Pension Fund D boosted its stake in Glaukos Corporation (NYSE:GKOS) by 4.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,905 shares of the medical instruments supplier’s stock after acquiring an additional 800 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Glaukos were worth $2,056,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in GKOS. Bessemer Group Inc. boosted its holdings in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 158 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 159 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Glaukos by 21.8% during the 1st quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier’s stock valued at $32,187,000 after buying an additional 58,502 shares in the last quarter. Capital Management Associates Inc bought a new stake in shares of Glaukos during the 1st quarter valued at $217,000. Finally, Valeo Financial Advisors LLC boosted its holdings in shares of Glaukos by 1.5% during the 1st quarter. Valeo Financial Advisors LLC now owns 7,817 shares of the medical instruments supplier’s stock valued at $769,000 after buying an additional 117 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of Glaukos stock opened at $77.27 on Thursday. The stock has a market cap of $4.43 billion, a price-to-earnings ratio of -46.83 and a beta of 0.76. The firm’s 50-day moving average is $85.58 and its 200 day moving average is $91.60. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm’s revenue for the quarter was up 38.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.28) EPS. Glaukos has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GKOS shares. Zacks Research cut shares of Glaukos from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. The Goldman Sachs Group started coverage on shares of Glaukos in a report on Wednesday, October 1st. They set a “buy” rating and a $103.00 target price on the stock. Wells Fargo & Company boosted their target price on shares of Glaukos from $86.00 to $92.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $116.92.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.